Skip to main content
Category

Treatments

ResearchTreatments

Daiichi Sankyo, AstraZeneca Begin Phase III Trial of Enhertu in HER2-Mutant NSCLC

*December 2021* NEW YORK – Daiichi Sankyo and AstraZeneca on Thursday said that the first patient with HER2-mutant advanced non-small cell lung cancer has received treatment in a Phase III trial comparing their antibody-drug conjugate trastuzumab deruxtecan (Enhertu) against an immunotherapy-chemotherapy combination in the first-line setting. The DESTINY-Lung04 trial is evaluating trastuzumab…
laurabbook@gmail.com
March 16, 2022
ResearchTreatments

Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy Designation in Patients with Metastatic EGFR-Mutated NSCLC

*December 2021* Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to patritumab deruxtecan (HER3-DXd), a potential first-in-class HER3 directed antibody drug conjugate (ADC), for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC)…
laurabbook@gmail.com
March 16, 2022
ResearchTreatments

Comparing EGFR tyrosine kinase inhibitor treatments in EGFR-mutated non-small cell lung cancer across Asian and non-Asian patients: a plain language summary

*December 2021* How people from different ethnic populations respond differently to treatments for a type of lung cancer called non-small cell lung cancer (also known as NSCLC). EGFR tyrosine kinase inhibitors (often shortened to EGFR TKI treatments) are a form of treatment for NSCLC called EGFR mutation-positive NSCLC. There are currently…
laurabbook@gmail.com
January 21, 2022
ResearchTreatments

New Clinical Trials

*January 2022* A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC WSD0922-FU for the Treatment…
laurabbook@gmail.com
January 21, 2022